Low- or no-opioid pain control is possible with EXPAREL
EXPAREL® (bupivacaine liposome injectable suspension), is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. When injected into the surgical site, EXPAREL turns off the body’s pain signals, numbing the area where surgery has occurred for several days following the procedure. To date, EXPAREL has been used in over 4.5 million patients.1
EXPAREL infiltration provides significant long-lasting pain control while reducing opioid use
EXPAREL vs bupivacaine HCI in total knee arthoplasty (TKA)2
Data from patients undergoing a soft-tissue surgery3,4
*Results vs placebo through 72 hours. Opioid reduction calculated based on geometric mean ratio.
Excellent results with EXPAREL in a single shot in interscalene brachial plexus nerve block
Significant postsurgical pain relief that lasts 48 hours with EXPAREL
VAS pain intensity scores with interscalene brachial plexus nerve block5
Primary endpoint was area under the curve (AUC) of the visual analog scale (VAS) pain intensity scores; 136 vs 254 (LSMD -118) for EXPAREL and placebo, respectively2,5PACU=postanesthesia care unit. LSMD=least squares mean difference. Results from a phase 3 double-blind, randomized, controlled trial that compared the postsurgical analgesia efficacy, safety, and pharmacokinetics of EXPAREL 133 mg (10 mL) and placebo in patients undergoing total shoulder arthroplasty or rotator cuff repair. Primary and secondary endpoints: pain intensity through 48 hours postsurgery, as measured by area under the curve (AUC) of visual analog scale (VAS) pain intensity scores and total postsurgical opioid consumption. Rescue opioids for pain were available upon patient request.
78% reduction in opioids through 48 hours
Postsurgical opioid consumption6
The clinical benefit of the decrease in opioid consumption was not demonstrated in the clinical trials